NanoLogix Cooperative Projects Update For EPA and University of Texas Health Science Center Houston

NanoLogix Quick Tests improving result times for Group B Strep

HUBBARD, OH, DECEMBER 13, 2010-- NanoLogix (PINK OTC Markets: NNLX), an innovator in the accelerated detection and identification of microorganisms, announces the current 300 patient trial of NanoLogix GBS (Group B Streptococcus) Quick Tests is ongoing at the University of Texas Health Science Center (UTHSC) in Houston. NanoLogix anticipates initial filings for GBS Quick-Test FDA approval following final publication of the GBS trial results. In addition, this month UTHSC Houston plans to expand its evaluation of NanoLogix Quick Tests, concurrent with the GBS trial, to include the superbug MRSA (formally known as Methicillin-resistant Staphylococcus aureus), with E.Coli and Pseudomonas to follow in early 2011. For further information on the GBS trial please visit the UTHSC - Houston Newsroom at:

NanoLogix Technology Focused on Domination of $150 Million U.S. Ob/Gyn GBS Testing Market

NanoLogix seeks to lead innovation in the market of GBS Ob/Gyn testing, which in the U.S. is valued at approximately $150 million annually. Initial results from UTHSC Houston last spring show the GBS Quick Tests returned reliable results in approximately four hours. With the current standard of 48-72 hours, this is a markedly significant reduction in testing time. Today’s GBS strains are resistant to ampicillin and amoxicillin and by improving standard detection speed, NanoLogix and the physicians at UTHSC Houston hope to dramatically reduce the overuse of antibiotics in pregnant women and contribute to the fight against GBS antibiotic resistance.

NanoLogix EPA CRADA To Continue Until 2012

NanoLogix is currently in the first phase of its work to assist the US Environmental Protection Agency (EPA) in the development of a comprehensive water quality test kit for use with surface and source waters. NanoLogix and the EPA have a Cooperative Research and Development Agreement (CRADA) with runs through 2012. For additional information please visit the internal news update archive at the EPA's Microbiological and Chemical Exposure Assessment Research Division (MCEARD):

NanoLogix Cincinnati Laboratory

NanoLogix is pleased to announce an operations evolution in its BioStart Cincinnati laboratory designed to better serve the needs of its clients, customers, and partners. The company has added new equipment and appointed Ahmer Kodvowala, MS, MBA as Director of Laboratory Operations. Hilda Diaz, MS, will continue to serve as Senior Researcher. Joining the laboratory as the new research assistant is Michael Sube, BA. NanoLogix doubled the size of its laboratory facility in July 2010 and added additional office space at that time. The current changes are in keeping with established expansion plans.

Dr. Sergey Gazenko has left the company for personal reasons. He is the author of 2 of NanoLogix 34 granted patents and 3 patents pending. Dr. Gazenko will provide consulting services to NanoLogix as needed.

About NanoLogix, Inc.

NanoLogix is a biotechnology company focused primarily on rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to medical and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing. Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity. For more information visit

More information on NanoLogix is available at:

This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.


Media Contact:
Lisa Ann Pinkerton

Investor Contact:
NanoLogix, Inc.
Investor Relations
Carol Surrena
Telephone: 330-534-0800

Copyright 2011 NanoLogix, Inc All Rights Reserved